The pilot study of neoadjuvant chemotherapy of FIRINOX for patients with borderline resectable pancreatic cancer
Not Applicable
- Conditions
- Invasive ductal carcinoma
- Registration Number
- JPRN-UMIN000013809
- Lead Sponsor
- Wakayama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Severe drug hypersensitivity (2)Multiple primary cancers within 5 years (3)Severe infection (4)With grade 2 or more severe peripheral neuropathy (5)With intestinal paralysys, ileus (6)Interstitial pneumonia or pulmonary (7)With uncontrollable pleural effusion or ascites (8)Receiving atazanavir sulfate (9)With uncontrollable diabetes (10)With uncontrollable heart failure, angina, hypertension, arrhythmia (11)With severe psychological symptoms (12)With watery diarrhea (13)Pregnant or lactating women, or women with known or suspected pregnancy (14)Inappropriate patients for entry on this study in the judgment of the investigator (15)With UGT1A1*28 and/or UGT1A1*6 polymorphisms
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (1)Adverse event
- Secondary Outcome Measures
Name Time Method (1)R0 resection rate (2)Resection rate (3)Optimal number of courses administration of neoadjuvant chemotherapy (4)Optimal duration of surgery to perform from neoadjuvant chemotherapy